Anders Bjartell
41 – 50 of 361
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Systematic Augmentation in HSV Space for Semantic Segmentation of Prostate Biopsies
2023) 22nd Scandinavian Conference on Image Analysis, SCIA 2023 In Lecture Notes in Computer Science 13886. p.293-308(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Salvage radiotherapy after radical prostatectomy : functional outcomes in the LAPPRO trial after 8-year follow-up
(
- Contribution to journal › Article
-
Mark
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
(
- Contribution to journal › Article
-
Mark
Re : Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Correlation between ADC, ADC ratio, and Gleason Grade group in prostate cancer patients undergoing radical prostatectomy : Retrospective multicenter study with different MRI scanners
(
- Contribution to journal › Article
- 2022
-
Mark
Risk of hernia formation after radical prostatectomy : a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial
(
- Contribution to journal › Article
-
Mark
Increasing rates of urinary- and bloodstream infections following transrectal prostate biopsy in South Sweden
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
-
Mark
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
(
- Contribution to journal › Article